Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells

被引:0
|
作者
Elham Masoumi
Leila Jafarzadeh
Hamid Reza Mirzaei
Khadijeh Alishah
Keyvan Fallah-Mehrjardi
Hosein Rostamian
Mohammad Khakpoor-Koosheh
Reza Meshkani
Farshid Noorbakhsh
Jamshid Hadjati
机构
[1] Tehran University of Medical Sciences,Department of Medical Immunology, School of Medicine
[2] University of Tehran,Department of Biotechnology, Faculty of Science
[3] Tehran University of Medical Sciences,Department of Clinical Biochemistry, School of Medicine
关键词
Mesothelin; Chimeric antigen receptor; Adenosine 2a-receptor; Genetic targeting; Pharmacological targeting; Tumor microenvironment;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [1] Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
    Masoumi, Elham
    Jafarzadeh, Leila
    Mirzaei, Hamid Reza
    Alishah, Khadijeh
    Fallah-Mehrjardi, Keyvan
    Rostamian, Hosein
    Khakpoor-Koosheh, Mohammad
    Meshkani, Reza
    Noorbakhsh, Farshid
    Hadjati, Jamshid
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [2] Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo
    Liu, Guodi
    Zhang, Qian
    Liu, Guoping
    Li, Dehua
    Zhang, Linsong
    Gu, Zhangjie
    Tian, Huixin
    Zhang, Yong
    Tian, Xiaoli
    [J]. EXPERIMENTAL CELL RESEARCH, 2021, 409 (01)
  • [3] Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells
    Jafarzadeh, Leila
    Masoumi, Elham
    Mirzaei, Hamid Reza
    Alishah, Khadijeh
    Fallah-Mehrjardi, Keyvan
    Khakpoor-Koosheh, Mohammad
    Rostamian, Hosein
    Noorbakhsh, Farshid
    Hadjati, Jamshid
    [J]. MOLECULAR IMMUNOLOGY, 2021, 139 : 1 - 9
  • [4] Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope
    Liu, X. F.
    Onda, M.
    Schlomer, J.
    Bassel, L.
    Kozlov, S.
    Tai, C. -H.
    Zhou, Q.
    Liu, W.
    Tsao, H. -E.
    Hassan, R.
    Ho, M.
    Pastan, I.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (04)
  • [5] Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
    Castelletti, Laura
    Yeo, Dannel
    van Zandwijk, Nico
    Rasko, John E. J.
    [J]. BIOMARKER RESEARCH, 2021, 9 (01)
  • [6] Challenges of Anti-Mesothelin CAR-T-Cell Therapy
    Zhai, Xuejia
    Mao, Ling
    Wu, Min
    Liu, Jie
    Yu, Shicang
    [J]. CANCERS, 2023, 15 (05)
  • [7] Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
    Laura Castelletti
    Dannel Yeo
    Nico van Zandwijk
    John E. J. Rasko
    [J]. Biomarker Research, 9
  • [8] Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer
    Jiannan Chen
    Jianhua Hu
    Lili Gu
    Feng Ji
    Fan Zhang
    Miaomiao Zhang
    Jun Li
    Zhengliang Chen
    Longwei Jiang
    Yan Zhang
    Ruifang Shi
    Lihua Ma
    Shaochang Jia
    Ying Zhang
    Qi Zhang
    Junqing Liang
    Shunyu Yao
    Zhigang Hu
    Zhigang Guo
    [J]. Cancer Immunology, Immunotherapy, 2023, 72 : 409 - 425
  • [9] Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer
    Chen, Jiannan
    Hu, Jianhua
    Gu, Lili
    Ji, Feng
    Zhang, Fan
    Zhang, Miaomiao
    Li, Jun
    Chen, Zhengliang
    Jiang, Longwei
    Zhang, Yan
    Shi, Ruifang
    Ma, Lihua
    Jia, Shaochang
    Zhang, Ying
    Zhang, Qi
    Liang, Junqing
    Yao, Shunyu
    Hu, Zhigang
    Guo, Zhigang
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (02) : 409 - 425
  • [10] Correction to: Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer
    Jiannan Chen
    Jianhua Hu
    Lili Gu
    Feng Ji
    Fan Zhang
    Miaomiao Zhang
    Jun Li
    Zhengliang Chen
    Longwei Jiang
    Yan Zhang
    Ruifang Shi
    Lihua Ma
    Shaochang Jia
    Ying Zhang
    Qi Zhang
    Junqing Liang
    Shunyu Yao
    Zhigang Hu
    Zhigang Guo
    [J]. Cancer Immunology, Immunotherapy, 2023, 72 : 3401 - 3403